TILT-123 Trial Shows Promise for Ovarian Cancer
Preliminary results from a Phase 1b trial reveal high response rates in patients with platinum-resistant ovarian cancer.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Should experimental drug combinations be prioritized to treat patients with limited standard options?
TILT Biotherapeutics has released Phase 1b data for its TILT-123 drug candidate, which is being studied for the treatment of platinum-resistant ovarian cancer. The combination therapy achieved a 44 percent overall response rate among evaluable patients in the study.
Why it matters
Platinum-resistant ovarian cancer currently faces limited therapeutic options, making new, effective treatment combinations critical for improving patient outcomes. These initial results provide a potential new pathway for addressing this difficult-to-treat malignancy.
The study evaluated 14 patients, with nine evaluable individuals showing a 78 percent disease control rate. Researchers recorded that four patients achieved confirmed partial responses, while two others converted to complete responses.
The players
TILT Biotherapeutics
This biotechnology company focuses on developing cancer immunotherapies based on oncolytic viruses.
ESMO Congress
This annual event is a leading international meeting for oncology professionals to discuss clinical research.
Mayo Clinic
This non-profit academic medical center is a global leader in clinical research and patient care.
The details
The experimental treatment involves TILT-123 administered alongside pembrolizumab and pegylated liposomal doxorubicin. Findings presented at the ESMO Congress 2026 detailed that one patient maintained a response for 12 months, with another patient reaching 21 months before disease progression.
Timeline
Patient enrollment in the Phase 1b study concluded in January 2026.
Results were publicly presented in October 2026.
The Big Picture
This research follows the patterns set by the ESMO 2026 clinical research program in advancing combination immunotherapy strategies. The data marks a departure from traditional single-agent chemotherapy approaches for platinum-resistant cases.
These results offer potential new treatment avenues for patients who have not responded to standard platinum-based therapies. While this is an early-stage study, it suggests future alternatives for those currently facing limited clinical options.
The takeaway
Ongoing clinical research continues to identify new combinations to treat resistant cancer subtypes. Patients should consult their oncologists about whether trial enrollment or newly approved combination therapies are appropriate for their specific diagnosis.
Further reading
Learn more about the latest research in the field of Cancer.
Source note: This article includes information reported by Scientist Live.
Live Poll
Should experimental drug combinations be prioritized to treat patients with limited standard options?
